Payment overview · 2025
General Payments
$952.85
37 reported records · 18 companies
Healthcare provider profile · identity verified
Albert Humphrey, MD
Allopathic & Osteopathic Physicians|Internal Medicine · COLUMBIA, SC · NPI 1770543621
Verified facts
What the public records show
CMS Open Payments records show Albert Humphrey, MD received $952.85 in general payments during 2025 across 37 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $251.70 | 26.4% | 7 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $113.50 | 11.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $102.94 | 10.8% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $77.37 | 8.1% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $57.70 | 6.1% | 3 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $50.00 | 5.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.70 | 4.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $44.19 | 4.6% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $33.90 | 3.6% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $30.57 | 3.2% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.01 | 2.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.67 | 2.4% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $19.01 | 2.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.89 | 1.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.87 | 1.8% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $16.37 | 1.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.19 | 1.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.27 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $952.85 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $179.82 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $113.50 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $112.52 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $80.50 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $77.37 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $57.70 | 3 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $50.00 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $44.70 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $44.70 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $40.64 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.61 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $33.90 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $23.01 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $22.85 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 105 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 34 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 97 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
105 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
97 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
107 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone Hcl | Oxycodone Hcl | 724 | 89 |
| Atorvastatin Calcium | Atorvastatin Calcium | 537 | 178 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 461 | 71 |
| Methadone Hcl | Methadone Hcl | 418 | 54 |
| Morphine Sulfate Er | Morphine Sulfate | 248 | 26 |
| Hydromorphone Hcl | Hydromorphone Hcl | 244 | 33 |
| Amlodipine Besylate | Amlodipine Besylate | 234 | 77 |
| Metformin Hcl | Metformin Hcl | 229 | 74 |
| Repatha Sureclick | Evolocumab | 210 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 201 | 69 |
| Gabapentin | Gabapentin | 200 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 199 | 60 |
| Carvedilol | Carvedilol | 197 | 70 |
| Furosemide | Furosemide | 195 | 74 |
| Losartan Potassium | Losartan Potassium | 184 | 63 |
| Spironolactone | Spironolactone | 179 | 69 |
| Lisinopril | Lisinopril | 178 | 59 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 172 | 24 |
| Ezetimibe | Ezetimibe | 169 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 163 | 63 |
| Oxycontin | Oxycodone Hcl | 142 | 16 |
| Potassium Chloride | Potassium Chloride | 139 | 54 |
| Alprazolam | Alprazolam | 135 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 132 | 52 |
| Fentanyl | Fentanyl | 129 | 13 |
| Xtampza Er | Oxycodone Myristate | 125 | 16 |
| Allopurinol | Allopurinol | 124 | 46 |
| Famotidine | Famotidine | 117 | 41 |
| Eliquis | Apixaban | 107 | 23 |
| Farxiga | Dapagliflozin Propanediol | 105 | 26 |
| Ozempic | Semaglutide | 97 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 28 |
| Donepezil Hcl | Donepezil Hcl | 91 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 81 | 24 |
| Clonidine Hcl | Clonidine Hcl | 80 | 24 |
| Omeprazole | Omeprazole | 76 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 70 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 62 | 21 |
| Tramadol Hcl | Tramadol Hcl | 62 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 27 |
| Benazepril Hcl | Benazepril Hcl | 61 | 19 |
| Metformin Hcl Er | Metformin Hcl | 61 | 19 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 58 | 24 |
| Simvastatin | Simvastatin | 58 | 20 |
| Meloxicam | Meloxicam | 53 | 20 |
| Valsartan | Valsartan | 52 | 17 |
| Januvia | Sitagliptin Phosphate | 50 | suppressed |
| Amoxicillin | Amoxicillin | 46 | 39 |
| Telmisartan | Telmisartan | 45 | 12 |
| Morphine Sulfate | Morphine Sulfate | 44 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 43 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 43 | 21 |
| Finasteride | Finasteride | 40 | 12 |
| Mirtazapine | Mirtazapine | 39 | 14 |
| Irbesartan | Irbesartan | 38 | 12 |
| Lorazepam | Lorazepam | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Baclofen | Baclofen | 37 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 11 |
| Nifedipine Er | Nifedipine | 37 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 15 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 20 |
| Glimepiride | Glimepiride | 34 | 13 |
| Jardiance | Empagliflozin | 34 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 34 | 11 |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Klor-Con M20 | Potassium Chloride | 32 | 14 |
| Repatha Pushtronex | Evolocumab | 31 | 17 |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | 12 |
| Sertraline Hcl | Sertraline Hcl | 30 | suppressed |
| Verapamil Er | Verapamil Hcl | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Prednisone | Prednisone | 21 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 17 | suppressed |
| Repaglinide | Repaglinide | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 15 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 13 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Propylthiouracil | Propylthiouracil | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Nateglinide | Nateglinide | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $952.85 · 37 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AUSTEDO XR, COMIRNATY, CeQur Simplicity, FARXIGA, FREESTYLE LIBRE 3, INJECTAFER, INTELLIS ADAPTIVESTIM, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NEXLETOL, NUZYRA, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, VERQUVO, VOQUEZNA, Veozah, WAINUA, Wegovy, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error